Arbutus Biopharma Corp
ABUS
Get informed when a big investor buys or sells
+ FollowMarket Cap$900.77M
Close$
$-3.14
172.2% downside
Current Fair Value
172.2% downsideOvervalued by 172.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $900.77 Million |
|---|---|
| Enterprise Value | $877.70 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.17 |
| Beta | 0.62 |
| Outstanding Shares | 193,768,641 |
Return
| Return on Equity | 61.77% |
|---|---|
| Return on Assets | 57.99% |
| Return on Invested Capital | 57.10% |
Valuation & Multiples
| P/E Ratio | 5.5 |
|---|---|
| PEG | -0.69 |
| Price to Sales | - |
| Price to Book Ratio | 4.35 |
| Enterprise Value to Revenue | 4.58 |
| Enterprise Value to EBIT | 5.65 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$750,000
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$650,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0895▲ 77.31% |
|---|---|
| Total Calls | 470,300▼ 83.15% |
| Total Puts | 512,400▼ 41.98% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 72.54%▲ 8.91% |
|---|---|
| Total Invested | $625.43M▲ 6.56% |
| Investors Holding | 175▼ 15.00% |
ESG Score
No data
About Arbutus Biopharma Corp
CEO: William Collier